百合育子方治疗少弱畸形精子症及其机理研究

注册号:

Registration number:

ITMCTR2200005977

最近更新日期:

Date of Last Refreshed on:

2022-05-06

注册时间:

Date of Registration:

2022-05-06

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

百合育子方治疗少弱畸形精子症及其机理研究

Public title:

Study on the treatment of oligoasmatospermia with Baihe Yuzi prescription and its mechanism

注册题目简写:

English Acronym:

研究课题的正式科学名称:

百合育子方治疗少弱畸形精子症及其机理研究

Scientific title:

Study on the treatment of oligoasmatospermia with Baihe Yuzi prescription and its mechanism

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200059662 ; ChiMCTR2200005977

申请注册联系人:

李波

研究负责人:

李波

Applicant:

Li Bo

Study leader:

Li Bo

申请注册联系人电话:

Applicant telephone:

+86 13933167318

研究负责人电话:

Study leader's telephone:

+86 13933167318

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

libodoc@126.com

研究负责人电子邮件:

Study leader's E-mail:

libodoc@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

河北省石家庄市长安区中山东路389号河北省中医院

研究负责人通讯地址:

河北省石家庄市长安区中山东路389号河北省中医院

Applicant address:

Hebei Hospital of Traditional Chinese Medicine, no. 389, East Zhongshan Road, Chang 'an District, Shijiazhuang city, Hebei Province

Study leader's address:

Hebei Hospital of Traditional Chinese Medicine, no. 389, East Zhongshan Road, Chang 'an District, Shijiazhuang city, Hebei Province

申请注册联系人邮政编码:

Applicant postcode:

050011

研究负责人邮政编码:

Study leader's postcode:

050011

申请人所在单位:

河北省中医院

Applicant's institution:

Hebei Provincial Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

HBZY2019-KY-147-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

河北省中医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Hebei Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2019/4/30 0:00:00

伦理委员会联系人:

胡靖楠

Contact Name of the ethic committee:

Hu jingnan

伦理委员会联系地址:

河北省石家庄市长安区中山东路389号河北省中医院

Contact Address of the ethic committee:

Hebei Hospital of Traditional Chinese Medicine, no. 389, East Zhongshan Road, Chang 'an District, Shijiazhuang city, Hebei Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

0311-69095606

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河北省中医院

Primary sponsor:

Hebei Hospital of Traditional Chinese Medicine, no. 389, East Zhongshan Road, Chang 'an District, Shijiazhuang city, Hebei Province

研究实施负责(组长)单位地址:

河北省石家庄市长安区中山东路389号河北省中医院

Primary sponsor's address:

Hebei Hospital of Traditional Chinese Medicine, no. 389, East Zhongshan Road, Chang 'an District, Shijiazhuang city, Hebei Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北省

市(区县):

Country:

china

Province:

Hebei province

City:

单位(医院):

河北省科学技术厅

具体地址:

石家庄市裕华东路105号

Institution
hospital:

Science and Technology Department of Hebei Province

Address:

105 Yuhua East Road, Shijiazhuang city

经费或物资来源:

河北省科学技术厅科研经费

Source(s) of funding:

Scientific research fund of Hebei Science and Technology Department

研究疾病:

男性不育

研究疾病代码:

Target disease:

Male infertility

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

观察百合育子方治疗无证可辨的特发性少精子症临床疗效及其对精液参数、精浆抗缪勒氏管激素、睾酮、雌二醇的影响

Objectives of Study:

To observe the clinical efficacy of Baihe Yuzi prescription in the treatment of idiopathic oligospermia and its effect on semen parameters and seminal plasma anti-mullerian hormone ,testosterone and estradiol.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

符合诊断标准,夫妻有规律性生活1年以上,未采取避孕措施不育,配偶检查无异常者;患者在进入临床研究前未使用改善精子质量的药物,或使用过但已经过了 3个月洗脱期者;血清性激素五项水平位于正常值以内;患者本人同意且签署知情同意书者

Inclusion criteria

Meet the diagnostic criteria, the husband and wife have been living regularly for more than one year, have no contraceptive measures and have no abnormalities in spouse examination; Patients who did not use drugs to improve sperm quality before entering the clinical study, or who have used drugs but have passed the washout period of 3 months; The five levels of serum sex hormones were within the normal value. The patient agrees and signs the informed consent

排除标准:

精索静脉曲张2级及以上者;有临床症状或舌苔脉象异常者;有腮腺炎病史或卵泡刺激素水平明显升高者;染色体或AZF基因异常者;不能脱离有毒、高温、放射线等特殊环境者;下丘脑、垂体发现肿瘤者。

Exclusion criteria:

Varicocele grade 2 and above; With clinical symptoms or abnormal tongue coating and pulse; A history of mumps or significantly elevated FSH levels; Chromosomal or AZF gene abnormality; Unable to escape from toxic, high temperature, radiation and other special environment; Tumors found in hypothalamus and pituitary gland.

研究实施时间:

Study execute time:

From 2019-05-06

To      2021-12-31

征募观察对象时间:

Recruiting time:

From 2019-06-01

To      2020-06-30

干预措施:

Interventions:

组别:

试验组

样本量:

55

Group:

experimental group

Sample size:

干预措施:

百合育子方

干预措施代码:

Intervention:

Baihe Yuzi Prescription

Intervention code:

组别:

对照组

样本量:

55

Group:

control group

Sample size:

干预措施:

枸橼酸氯米芬片联合五子衍宗丸

干预措施代码:

Intervention:

Clomiphene citrate tablets combined with Wuzi Yanzong pills

Intervention code:

样本总量 Total sample size : 110

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河北省

市(区县):

Country:

Province:

City:

单位(医院):

河北省中医院

单位级别:

省级

Institution/hospital:

Level of the institution:

测量指标:

Outcomes:

指标中文名:

精浆抗苗勒管激素

指标类型:

主要指标

Outcome:

seminal plasma anti-mullerian hormone

Type:

Primary indicator

测量时间点:

治疗开始前和结束后

测量方法:

化学发光法

Measure time point of outcome:

Before and after treatment

Measure method:

Chemiluminescence

指标中文名:

精浆睾酮、雌二醇

指标类型:

次要指标

Outcome:

Seminal plasma testosterone, estradiol

Type:

Secondary indicator

测量时间点:

治疗开始前和结束后

测量方法:

化学发光法

Measure time point of outcome:

Before and after treatment

Measure method:

Chemiluminescence

指标中文名:

精液参数

指标类型:

主要指标

Outcome:

semen parameters

Type:

Primary indicator

测量时间点:

治疗开始前和结束后

测量方法:

计算机辅助

Measure time point of outcome:

Before and after treatment

Measure method:

Computer aided

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

精液

组织:

Sample Name:

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 24
Min age years
最大 39
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男性

Male

随机方法(请说明由何人用什么方法产生随机序列):

由不参加试验研究不知情者采用随机数字表法产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Random sequence was generated by random number table method from department members who did not participate in the study and did not know about it

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年4月上传到临床试验公共管理平台ResMan (www.medresman.org)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

April 2022 Upload to Clinical Trials Public Management platform ResMan (www.medresman.org)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用病例记录表记录原始数据,采用EXCEL表处理数据,统计软件分析数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The original data were recorded in the Case Record Form, processed in EXCEL, and analyzed by statistical software

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统